美国骨科外科委员会第二部分候选者报告的全髋与全膝关节置换术中静脉血栓栓塞预防策略的使用模式、疗效与并发症
分析2014至2016年美国骨科外科委员会第二部分考试病例数据库中22072例初次全髋和全膝关节置换术病例,比较激进与不激进静脉血栓栓塞预防策略的使用模式及并发症。不激进策略占45.4%,激进策略占54.6%,存在地区差异;激进策略与更高的血栓和出血并发症及90天内死亡相关,而不激进策略未与更高的血栓形成率相关。
要点
- 不激进静脉血栓栓塞预防策略占45.4%,激进策略占54.6%,6个地区间存在显著差异。
- 不激进策略以阿司匹林联合序贯加压装置为主(84.8%),单用阿司匹林占14.8%。
- 激进策略与更高的轻度血栓(0.9% vs 0.2%)、轻度出血(1.3% vs 0.4%)等并发症相关。
核心结论
- 无法确定采用更激进静脉血栓栓塞预防策略的个体原因,但更激进策略与更高的出血和血栓并发症发生率相关。
- 不激进策略未与更高的血栓形成率相关。
研究设计与样本
- 查询美国骨科外科委员会病例数据库,使用当前操作术语代码27447和27130分别筛选初次全膝关节和全髋关节置换术病例。
- 获取地理区域、患者年龄、性别、深静脉血栓预防策略和并发症信息,共分析2014至2016年22072例初次关节置换术病例。
- 仅使用阿司匹林和/或序贯加压装置者视为不激进预防模式,使用低分子量肝素(依诺肝素)、华法林、利伐沙班、磺达肝癸钠或其他策略者视为激进预防模式。
主要发现
- 全国不激进静脉血栓栓塞预防策略使用率为45.4%,激进策略使用率为54.6%。
- 6个地区间预防策略模式存在显著差异。
- 不激进策略主要模式为阿司匹林联合序贯加压装置占84.8%,单用阿司匹林占14.8%。
- 使用不激进预防策略与患者无并发症显著相关(95.5% vs 93.0%)。
- 使用激进预防模式与更高的轻度血栓(0.9% vs 0.2%)、轻度出血(1.3% vs 0.4%)、中度血栓(1.2% vs 0.4%)、中度出血(2.7% vs 2.1%)、重度血栓(0.1% vs 0.0%)、重度出血事件(1.2% vs 0.9%)、感染(1.9% vs 1.3%)及90天内死亡(0.7% vs 0.3%)可能性相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无法确定采用更激进静脉血栓栓塞预防策略的个体原因。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many strategies for venous thromboembolism (VTE) prophylaxis following hip and knee arthroplasty exist, with extensive controversy regarding the optimum strategy to minimize risk of VTE and bleeding complications. Data from the American Board of Orthopedic Surgery Part II (oral) Examination case list database was analyzed to determine efficacy, complication rates, and prescribing patterns for different prophylactic strategies. METHODS: The American Board of Orthopedic Surgery case database was queried utilizing Current Procedural Terminology codes 27447 and 27130 for primary total knee and hip arthroplasty, respectively. Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained. Less aggressive prophylaxis patterns were considered if only aspirin and/or sequential compression devises were utilized. More aggressive VTE prophylaxis patterns were considered if any of low-molecular-weight heparin (enoxaparin), warfarin, rivaroxaban, fondaparinux, or other strategies was used. RESULTS: In total, 22,072 cases of primary joint arthroplasty were analyzed from 2014 to 2016. The national rate of less aggressive VTE prophylaxis strategies was 45.4%, while more aggressive strategies were used in 54.6% of patients. Significant regional differences in prophylactic strategy patterns exist between the 6 regions. The predominant less aggressive prophylaxis pattern was aspirin with sequential compression devises at 84.8% with 14.8% receiving aspirin alone. Use of less aggressive prophylaxis strategy was significantly associated with patients having no complications (95.5% vs 93.0%). Use of more aggressive prophylaxis patterns was associated with higher likelihood of mild thrombotic (0.9% vs 0.2%), mild bleeding (1.3% vs 0.4%), moderate thrombotic (1.2% vs 0.4%), moderate bleeding (2.7% vs 2.1%), severe thrombotic (0.1% vs 0.0%), severe bleeding events (1.2% vs 0.9%), infections (1.9% vs 1.3%), and death within 90 days (0.7% vs 0.3%). Similar results were found in subgroup analysis of total hip and knee arthroplasty patients. CONCLUSION: It was not possible to ascertain the individual rationale for use of more aggressive VTE prophylaxis strategies; however, more aggressive strategies were associated with higher rates of bleeding and thrombotic complications. Less aggressive strategies were not associated with a higher rate of thrombosis. LEVEL OF EVIDENCE: Therapeutic Level III. DISCLAIMER: All views expressed in the study are the sole views of the authors and do not represent the views of the American Board of Orthopedic Surgery.
引用
- Runner RP, Gottschalk MB, Staley CA, et al. Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. J Arthroplasty. 2018. PMID: 30685257. doi:10.1016/j.arth.2018.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。